Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Improving Profitability ⢠Rising Leverage ⢠Negative Cash Flow TEM's profitability is improving, but persistent operating losses, negative cash flow, rising leverage, and a demanding valuation warrant caution despite strong liquidity.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly rally ⢠Key breakout test ⢠Near-term support Support Level: $61.25â$62.27 Resistance Level: $72.69 TEM is bullish over the last month, holding above ~$60.95, but needs to break $72.69 to resume upside; watch $61.25â$62.27 support for trend weakness.
Sentiment & News
Key News Insights: ⢠Raised 2026 guidance ⢠First GAAP profit ⢠Personalis acquisition Tempus AI's stronger guidance, first GAAP profit, and Personalis deal momentum support a bullish outlook, though elevated valuation and cash-burn risks warrant caution.
AI Summary
TEM's upside now hinges on proving that FDA/reimbursement gains and the Personalis deal can convert oncology diagnostics into recurring, cash-generative workflow revenue; investors should wait for sustained positive operating cash flow and measurable integration synergies, as the premium valuation and $1.44B debt leave limited room for execution misses.
Description
Tempus AI, Inc. is a healthcare technology company that performs molecular diagnostics, including next-generation sequencing, PCR profiling, genotyping and anatomic pathology for healthcare providers, pharmaceutical and biotechnology firms, and researchers. It also licenses a de-identified, linked clinicalâmolecularâimaging dataset and offers analytics, cloud compute tools, clinical trial matching, algorithmic oncology tests and software for test ordering and research workflows. The company entered strategic collaborations with AstraZeneca and Pathos AI, was incorporated in 2015, changed its name from Tempus Labs in January 2023, and is headquartered in Chicago, Illinois.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 9 | Dec 16 | TEM | Tempus AI, Inc. | Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential. | Closed | -10.2% |